Immutep Limited (NASDAQ: IMMP) Receives FDA Orphan Drug Status for Soft Tissue Sarcoma Treatment
Key Developments Immutep Limited (NASDAQ: IMMP), a biotechnology firm focused on therapies for cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration has granted its drug eftilagimod alfa Orphan Drug Designation. This recognition applies to the treatment of Soft Tissue Sarcoma (STS), a rare form of cancer with high unmet medical needs. The designation aims to expedite the development and regulatory review process for eftilagimod alfa, enhancing…
